Literature DB >> 1478792

Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation.

V V Tertov1, I A Sobenin, A N Orekhov.   

Abstract

The properties of sialylated (sialic acid rich) and desialylated (sialic acid poor) fractions of low-density lipoproteins (LDL) isolated from blood plasma of healthy subjects and coronary atherosclerosis patients have been investigated. Sialylated (60-90% of total LDL) and desialylated (10-40%) LDL were separated by affinity chromatography on Ricinus communis agglutinin-agarose. Sialic acid contents in sialylated LDL fractions of healthy subjects and patients were found to be the same, and 1.5 to 3-fold higher than in desialylated LDL. Desialylated LDL had smaller sizes and greater electrophoretic mobility than sialylated, ones. Desialylated, but not sialylated, LDL induced 1.5 to 4-fold accumulation of neutral lipids in human aortic smooth-muscle cells. Desialylated LDL contained lower amounts of cholesteryl esters, free cholesterol and triglycerides as compared to sialylated LDL. On the other hand, the concentrations of di-, monoglycerides and free fatty acids in desialylated LDL were 2 to 3-fold higher than in sialylated lipoproteins. The desialylated LDL fraction was characterized by lower levels of phosphatidylcholine, sphingomyelin and phosphatidylethanolamine, but a higher content of lysophosphatidylcholine. Levels of thiobarbituric acid-reactive substances in freshly isolated desialylated and sialylated LDL were the same. Desialylated LDL had a higher level of oxysterols and lower amounts of vitamins A and E. The content of free amino groups of lysine in desialylated LDL of patients was 2-fold lower than in sialylated LDL. The results of this study demonstrate that multiple physico-chemical parameters of desialylated LDL differ from those of sialylated LDL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478792

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  6 in total

1.  Anti-atherosclerotic therapy based on botanicals.

Authors:  Alexander N Orekhov; Igor A Sobenin; Nikolay V Korneev; Tatyana V Kirichenko; Veronika A Myasoedova; Alexandra A Melnichenko; Mercedes Balcells; Elazer R Edelman; Yuri V Bobryshev
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2013-04

2.  Mutation in ST6GALNAC5 identified in family with coronary artery disease.

Authors:  Kolsoum InanlooRahatloo; Amir Farhang Zand Parsa; Klaus Huse; Paniz Rasooli; Saeid Davaran; Matthias Platzer; Marcel Kramer; Jian-Bing Fan; Casey Turk; Sasan Amini; Frank Steemers; Kevin Gunderson; Mostafa Ronaghi; Elahe Elahi
Journal:  Sci Rep       Date:  2014-01-08       Impact factor: 4.379

Review 3.  Cholesterol in the Cell Membrane-An Emerging Player in Atherogenesis.

Authors:  Karel Paukner; Ivana Králová Lesná; Rudolf Poledne
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

Review 4.  Lipoprotein sialylation in atherosclerosis: Lessons from mice.

Authors:  Liming Yu; Jun Peng; Chieko Mineo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

Review 5.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

Review 6.  Sialic acid metabolism as a potential therapeutic target of atherosclerosis.

Authors:  Chao Zhang; Jingyuan Chen; Yuhao Liu; Danyan Xu
Journal:  Lipids Health Dis       Date:  2019-09-14       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.